Figure 1.

Trial design, treatment regimen, and disposition of patients throughout pathfinder2 *215 patients were screened, 186 (161 adults, 25 adolescents) were treated with N8‐GP during pathfinder2. **patients with ≤2 bleeding episodes within the last 6 months on the Q4D regimen could switch to Q7D dosing. Patients on Q7D treatment who experienced ≥2 spontaneous bleeds or 1 severe bleed requiring hospitalization over an 8‐week period were switched back to Q4D treatment. Q4D, every fourth day treatment; Q7D, weekly treatment; R, randomization